Population screening for variant Creutzfeldt-Jakob disease using a novel blood test: Diagnostic accuracy and feasibility study

JAMA Neurology

Volumn 71, Issue 4, 2014, Pages 421-428

  Jackson, Graham S ^a   Burk Rafel, Jesse ^a,b   Edgeworth, Julie Ann ^a   Sicilia, Anita ^a   Abdilahi, Sabah ^a   Korteweg, Justine ^a   Mackey, Jonathan ^a   Thomas, Claire ^a   Wang, Guosu ^a   Schott, Jonathan M ^a   Mummery, Catherine ^a   Chinnery, Patrick F ^c   Mead, Simon ^a,d   Collinge, John ^a,d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD DONOR; BLOOD EXAMINATION; BLOOD SAMPLING; BOVINE SPONGIFORM ENCEPHALOPATHY; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC ACCURACY; FEASIBILITY STUDY; HUMAN; MAJOR CLINICAL STUDY; MASS SCREENING; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; UNITED KINGDOM; UNITED STATES; VARIANT CREUTZFELDT JAKOB DISEASE;

ANIMALS; CATTLE; COHORT STUDIES; CREUTZFELDT-JAKOB SYNDROME; CROSS-SECTIONAL STUDIES; FEASIBILITY STUDIES; GREAT BRITAIN; HEMATOLOGIC TESTS; HUMANS; POPULATION SURVEILLANCE; PRION DISEASES; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84898981975     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2013.6001     Document Type: Article

References (52)

1. McKinley MP, Bolton DC, Prusiner SB. A protease-resistant protein is a structural component of the scrapie prion. Cell. 1983;35(1): 57-62. (Pubitemid 14240218)
2. Hill AF, Desbruslais M, Joiner S, et al. The same prion strain causes vCJD and BSE. Nature. 1997;389(6650):448-450, 526. (Pubitemid 27435311)
3. Bruce ME, Will RG, Ironside JW, et al. Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature. 1997;389(6650): 498-501. (Pubitemid 27435325)
4. Ghani AC, Donnelly CA, Ferguson NM, Anderson RM. The transmission dynamics of BSE and vCJD. C R Biol. 2002;325(1): 37-47.
5. Wadsworth JD, Joiner S, Hill AF, et al. Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay. Lancet. 2001;358(9277): 171-180. (Pubitemid 32718539)
6. Hilton DA, Ghani AC, Conyers L, et al. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. J Pathol. 2004;203(3): 733-739. (Pubitemid 38961558)
7. Spongiform Encephalopathy Advisory Committee. SEAC 100/6 Prevalence: Resolving the Discrepancy in Current Estimates. London, England: Spongiform Encephalopathy Advisory Committee; 2008.
8. Spongiform Encephalopathy Advisory Committee. SEAC 100/2: Combining Evidence From Tissue Surveys to Estimate Prevalence of Subclinical vCJD. London, England: Spongiform Encephalopathy Advisory Committee; 2008.
9. Summary results of the second national survey of abnormal prion prevalence in archived appendix specimens. Health Protection Report website. http://www.hpa.org.uk/hpr/archives/2012 /news3212.htm#bnrmlprn.
10. Gill ON, Spencer Y, Richard-Loendt A, et al. Prevalent abnormal prion protein in human appendixes after bovine spongiform encephalopathy epizootic: large scale survey. BMJ. 2013;347:f5675.
11. Collinge J. Cell biology: the risk of prion zoonoses. Science. 2012;335(6067): 411-413.
12. Collinge J, Whitfield J, McKintosh E, et al. Kuru in the 21st century: an acquired human prion disease with very long incubation periods. Lancet. 2006;367(9528): 2068-2074. (Pubitemid 43949290)
13. Collinge J, Palmer MS, Dryden AJ. Genetic predisposition to iatrogenic Creutzfeldt-Jakob disease. Lancet. 1991;337(8755): 1441-1442.
14. Palmer MS, Dryden AJ, Hughes JT, Collinge J. Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease. Nature. 1991;352(6333): 340-342. (Pubitemid 21912354)
15. Mead S, Stumpf MP, Whitfield J, et al. Balancing selection at the prion protein gene consistent with prehistoric kurulike epidemics. Science. 2003;300(5619): 640-643. (Pubitemid 36520588)
16. Collinge J. Molecular neurology of prion disease. J Neurol Neurosurg Psychiatry. 2005;76(7): 906-919. (Pubitemid 40909547)
17. Mead S, Uphill J, Beck J, et al. Genome-wide association study in multiple human prion diseases suggests genetic risk factors additional to PRNP. Hum Mol Genet. 2012;21(8): 1897-1906.
18. Lloyd SE, Maytham EG, Pota H, et al. HECTD2 is associated with susceptibility to mouse and human prion disease. PLoS Genet. 2009;5(2):e1000383.
19. Lloyd S, Mead S, Collinge J. Genetics of prion disease. Top Curr Chem. 2011;305: 1-22.
20. Hill AF, Joiner S, Linehan J, Desbruslais M, Lantos PL, Collinge J. Species-barrier-independent prion replication in apparently resistant species. Proc Natl Acad Sci U S A. 2000;97(18): 10248-10253.
21. Race R, Raines A, Raymond GJ, Caughey B, Chesebro B. Long-term subclinical carrier state precedes scrapie replication and adaptation in a resistant species: analogies to bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease in humans. J Virol. 2001;75(21): 10106-10112. (Pubitemid 32948040)
22. Béringue V, Herzog L, Jaumain E, et al. Facilitated cross-species transmission of prions in extraneural tissue. Science. 2012;335(6067): 472-475.
23. Peden AH, HeadMW, Ritchie DL, Bell JE, Ironside JW. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet. 2004;364(9433): 527-529. (Pubitemid 39070413)
24. Llewelyn CA, Hewitt PE, Knight RS, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet. 2004;363(9407): 417-421. (Pubitemid 38210057)
25. Wroe SJ, Pal S, Siddique D, et al. Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: A case report. Lancet. 2006;368(9552): 2061-2067. (Pubitemid 44855106)
26. Houston F, McCutcheon S, Goldmann W, et al. Prion diseases are efficiently transmitted by blood transfusion in sheep. Blood. 2008;112(12): 4739-4745.
27. Andréoletti O, Litaise C, Simmons H, et al. Highly efficient prion transmission by blood transfusion. PLoS Pathog. 2012;8(6):e1002782.
28. Brown P, Rohwer RG, Dunstan BC, MacAuley C, Gajdusek DC, Drohan WN. The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy. Transfusion. 1998;38(9): 810-816. (Pubitemid 28421640)
29. Tattum MH, Jones S, Pal S, Khalili-Shirazi A, Collinge J, Jackson GS. A highly sensitive immunoassay for the detection of prion-infected material in whole human blood without the use of proteinase K. Transfusion. 2010;50(12): 2619-2627.
30. Isaacs JD, Jackson GS, Altmann DM. The role of the cellular prion protein in the immune system. Clin Exp Immunol. 2006;146(1): 1-8. (Pubitemid 44393831)
31. Edgeworth JA, Jackson GS, Clarke AR, Weissmann C, Collinge J. Highly sensitive, quantitative cell-based assay for prions adsorbed to solid surfaces. Proc Natl Acad Sci U S A. 2009;106(9): 3479-3483.
32. Edgeworth JA, Farmer M, Sicilia A, et al. Detection of prion infection in variant Creutzfeldt-Jakob disease: A blood-based assay. Lancet. 2011;377(9764): 487-493.
33. European Commission DG Health and Consumer Directorate. Guideline for the CE marking of blood based in vitro diagnostic medical devices for vCJD based on detection of abnormal PrP. http://ec.europa.eu/health/medical-devices /files/meddev/2-14-4-ol-en.pdf. Published January 2012.
34. Collinge J, Gorham M, Hudson F, et al. Safety and efficacy of quinacrine in human prion disease (PRION-1 study): A patient-preference trial. Lancet Neurol. 2009;8(4): 334-344.
35. The National Prion Monitoring Cohort (NPMC). MRC Prion Unit website. http://www.prion.ucl.ac.uk /clinic-services/research/npmc/.
36. Poser S, Mollenhauer B, Kraubeta A, et al. How to improve the clinical diagnosis of Creutzfeldt-Jakob disease. Brain. 1999;122 (pt 12): 2345-2351.
37. Zerr I, Kallenberg K, Summers DM, et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain. 2009;132 (pt 10): 2659-2668.
38. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26:404-413. doi:10.2307/2331986.
39. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998;17(8): 857-872. (Pubitemid 28185165)
40. Haldane JBS. The estimation and significance of the logarithm of a ratio of frequencies. Ann Hum Genet. 1956;20(4): 309-311.
41. Simel DL, Samsa GP, Matchar DB. Likelihood ratios with confidence: sample size estimation for diagnostic test studies. J Clin Epidemiol. 1991;44(8): 763-770.
42. Deeks JJ, Altman DG. Diagnostic tests 4: likelihood ratios. BMJ. 2004;329(7458): 168-169.
43. Deeks JJ. Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests. BMJ. 2001;323(7305): 157-162. (Pubitemid 32678396)
44. Brown P. Blood infectivity, processing and screening tests in transmissible spongiform encephalopathy. Vox Sang. 2005;89(2): 63-70. (Pubitemid 41153020)
45. Glatzel M, Abela E, Maissen M, Aguzzi A. Extraneural pathologic prion protein in sporadic Creutzfeldt-Jakob disease. N Engl J Med. 2003;349(19): 1812-1820. (Pubitemid 37362957)
46. Guntz P, Walter C, Schosseler P, Morel P, Coste J, Cazenave JP. Feasibility study of a screening assay that identifies the abnormal prion protein PrPTSE in plasma: initial results with 20, 000 samples. Transfusion. 2010;50(5): 989-995.
47. Gregori L. A prototype assay to detect vCJD-infected blood. Lancet. 2011;377(9764): 444-446.
48. Saá P, Castilla J, Soto C. Presymptomatic detection of prions in blood. Science. 2006;313(5783): 92-94. (Pubitemid 44051260)
49. Hewitt PE, Llewelyn CA, Mackenzie J, Will RG. Creutzfeldt-Jakob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiological Review study. Vox Sang. 2006;91(3): 221-230. (Pubitemid 44337279)
50. Duncan RE, Delatycki MB, Collins SJ, Boyd A, Masters CL, Savulescu J. Ethical considerations in presymptomatic testing for variant CJD. J Med Ethics. 2005;31(11): 625-630. (Pubitemid 41701031)
51. Parliamentary questions. 16-5-2011. http://www.publications.parliament. uk/pa /cm201011/cmhansrd/cm110516/text /110516w0003.htm. Accessed January 3, 2014.
52. Parliamentary questions. 1-3-2011. CJD. http://www.publications. parliament.uk/pa /cm201011/cmhansrd/cm110301/text /110301w0003.htm. Published March 1, 2011. Accessed January 28, 2013.